title: Neuroprotection of rat retinal ganglion cells mediated through alpha7 nicotinic acetylcholine receptors.
abstract: Glutamate-induced excitotoxicity is thought to play an important role in several neurodegenerative diseases in the central nervous system (CNS). In this study, neuroprotection against glutamate-induced excitotoxicity was analyzed using acetylcholine (ACh), nicotine and the α7 specific nicotinic acetylcholine receptor (α7 nAChR) agonist, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride (PNU-282987), in cultured adult rat retinal neurons. Adult Long Evans rat retinas were dissociated and retinal ganglion cells (RGCs) were isolated from all other retinal tissue using a two-step panning technique. Once isolated, RGCs were cultured under various pharmacological conditions to demonstrate excitotoxicity and neuroprotection against excitotoxicity. After 3 days, RGCs were immunostained with antibodies against the glycoprotein, Thy 1.1, counted and cell survival was assessed relative to control untreated conditions. 500 μM glutamate induced excitotoxicity in large and small RGCs in an adult rat dissociated culture. After 3 days in culture with glutamate, the cell survival of large RGCs decreased by an average of 48.16% while the cell survival of small RGCs decreased by an average of 42.03%. Using specific glutamate receptor agonists and antagonists, we provide evidence that the excitotoxic response was mediated through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainic acid (KA) and N-methyl-d-aspartate (NMDA) glutamate receptors through an apoptotic mechanism. However, the excitotoxic effect of glutamate on all RGCs was eliminated if cells were cultured for an hour with 10 μM ACh, 100 μM nicotine or 100 nM of the α7 nAChR agonist, PNU-282987, before the glutamate insult. Inhibition studies using 10nM methyllycaconitine (MLA) or α-bungarotoxin (α-Bgt) supported the hypothesis that neuroprotection against glutamate-induced excitotoxicity on rat RGCs was mediated through α7 nAChRs. In immunocytochemical studies, double-labeled experiments using antibodies against Thy 1.1 and α7 nAChR subunits demonstrated that both large and small RGCs contained α7 nAChR subunits. The data presented in this study support the hypothesis that ACh and nicotinic acetylcholine receptor (nAChR) agonists provide neuroprotection against glutamate-induced excitotoxicity in adult rat RGCs through activation of α7 nAChR subunits. These studies lay the groundwork required for analyzing the effect of specific α7 nAChR agonists using in vivo models of excitotoxicity. Understanding the type of ACh receptors involved in neuroprotection in the rat retina could ultimately lead to therapeutic treatment for any CNS disease that involves excitotoxicity.
authors: Western Michigan University, Department of Biological Sciences, Kalamazoo, MI 49008, USA.
authors: K
authors: K
authors: Iwamoto
authors: D
authors: D
authors: Mata
authors: D M
authors: DM
authors: Linn
authors: C L
authors: CL
authors: Linn
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000109:Acetylcholine / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D002478:Cells, Cultured; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D018698:Glutamic Acid / Q000633:toxicity; D020287:In Situ Nick-End Labeling; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology; D051381:Rats; D020318:Rats, Long-Evans; D011978:Receptors, Nicotinic / Q000378:metabolism*; D012160:Retina / Q000166:cytology*; D012165:Retinal Ganglion Cells / Q000187:drug effects / Q000378:metabolism*; D013997:Time Factors; D064569:alpha7 Nicotinic Acetylcholine Receptor
chemical_list: D001549:Benzamides; D001643:Bridged Bicyclo Compounds; C579165:Chrna7 protein, rat; D018696:Neuroprotective Agents; D018722:Nicotinic Agonists; C498513:PNU-282987; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; D018698:Glutamic Acid; D016291:Dizocilpine Maleate; D009538:Nicotine; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D000109:Acetylcholine
references: J Physiol. 1998 Mar 15;507 ( Pt 3):749-57
references: 9508836
references: J Neurosci. 1993 Feb;13(2):442-54
references: 8426223
references: J Neurosci. 1993 May;13(5):1888-98
references: 8478682
references: BMC Neurosci. 2007 Jan 29;8:11
references: 17261189
references: Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1835-42
references: 12036987
references: J Neurochem. 2008 Jun;105(5):1924-38
references: 18266937
references: Proc R Soc Lond B Biol Sci. 1984 Nov 22;223(1230):79-100
references: 6083567
references: Annu Rev Pharmacol Toxicol. 2003;43:545-84
references: 12415125
references: Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4515-22
references: 18566471
references: Am J Ophthalmol. 1984 Jun;97(6):730-7
references: 6731537
references: Neuroscience. 2011 Jan 13;172:387-97
references: 21044663
references: Brain Res Mol Brain Res. 1991 Apr;10(1):61-70
references: 1647484
references: Annu Rev Neurosci. 1993;16:403-43
references: 7681637
references: Surv Ophthalmol. 1980 May-Jun;24(6):621-64
references: 7414505
references: Annu Rev Physiol. 1995;57:521-46
references: 7778876
references: Invest Ophthalmol Vis Sci. 1999 Apr;40(5):990-5
references: 10102297
references: Neuroscience. 2006;138(1):17-24
references: 16359816
references: J Comp Neurol. 1988 Jan 8;267(2):269-80
references: 3343401
references: Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2074-84
references: 11481275
references: Neuroscience. 1984 Apr;11(4):847-55
references: 6146113
references: J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61-74
references: 15665416
references: Exp Eye Res. 2010 Nov;91(5):554-66
references: 20800593
references: Curr Opin Neurobiol. 1991 Aug;1(2):258-62
references: 1687958
references: J Pharmacol Exp Ther. 1993 Jun;265(3):1455-73
references: 8510022
references: J Neurosci Methods. 2007 Jan 15;159(1):35-42
references: 16876874
references: J Comp Neurol. 1980 Jul 15;192(2):211-7
references: 7400395
references: J Comp Neurol. 1997 Aug 25;385(2):309-23
references: 9268130
references: Eur J Neurosci. 2011 Oct;34(8):1212-21
references: 21978141
references: Neuropharmacology. 2000 Oct;39(13):2799-807
references: 11044750
references: Cell Mol Neurobiol. 2012 Mar;32(2):191-200
references: 21822733
references: Prog Retin Eye Res. 1998 Oct;17(4):465-83
references: 9777647
references: J Med Chem. 2005 Feb 24;48(4):905-8
references: 15715459
references: Prog Neurobiol. 1998 Mar;54(4):369-415
references: 9522394
references: Neuron. 2001 Jun;30(3):771-80
references: 11430810
references: Biochim Biophys Acta. 1997 Apr 21;1345(3):223-36
references: 9150243
references: Curr Neuropharmacol. 2006 Apr;4(2):139-47
references: 18615127
references: J Comp Neurol. 1992 Oct 15;324(3):322-35
references: 1383291
references: Vis Neurosci. 1990 Jan;4(1):75-93
references: 2176096
references: J Neurochem. 2008 Mar;104(5):1177-89
references: 17986230
references: Neurosci Lett. 1992 Apr 13;138(1):179-82
references: 1407659
references: Invest Ophthalmol Vis Sci. 1999 May;40(6):1170-6
references: 10235550
references: J Alzheimers Dis. 2002 Oct;4(5):405-15
references: 12446972
references: Brain Behav Evol. 1985;26(1):10-48
references: 3902145
references: J Exp Biol. 1991 Jul;158:509-30
references: 1919416
references: J Physiol. 1965 Jun;178(3):477-504
references: 5827909
references: Prog Retin Eye Res. 1999 Jan;18(1):39-57
references: 9920498
references: Neuroscience. 2004;125(3):583-90
references: 15099672
references: J Glaucoma. 2010 Mar;19(3):151-7
references: 19223786
references: J Physiol. 2006 Sep 1;575(Pt 2):543-54
references: 16777935
references: Behav Brain Res. 2000 Aug;113(1-2):117-20
references: 10942038
references: Brain Res. 2001 Jun 15;904(1):177-88
references: 11516428
references: Eur Cytokine Netw. 2000 Jun;11(2):267-74
references: 10903806
references: J Physiol. 1974 Jul;240(2):397-419
references: 4422168
references: Brain Res. 1995 May 22;680(1-2):23-35
references: 7663981
references: J Neurochem. 2002 May;81(3):655-8
references: 12065674
references: Cell Death Dis. 2010;1:e27
references: 21364635
references: J Neurophysiol. 1999 Sep;82(3):1124-32
references: 10482732
references: J Neurochem. 2010 Jan;112(1):214-26
references: 19845831
references: J Comp Neurol. 2006 Oct 20;498(6):810-20
references: 16927255
references: Am J Vet Res. 1997 Aug;58(8):864-7
references: 9256971
references: Brain Res. 1983 Feb 14;261(1):138-44
references: 6301622
references: Brain Res. 1984 Apr 16;297(2):381-6
references: 6326945
references: Jpn J Physiol. 1995;45(3):491-508
references: 7474530
references: Ann N Y Acad Sci. 1996 Jan 17;777:356-61
references: 8624112
references: Eye (Lond). 2005 Apr;19(4):369-70
references: 15806116
references: J Pharmacol Exp Ther. 2002 Sep;302(3):889-97
references: 12183644
references: J Neurosci Methods. 1993 Nov;50(2):205-16
references: 8107502
references: Vis Neurosci. 1991 Jul-Aug;7(1-2):155-69
references: 1931799
references: Cell Calcium. 1998 Nov-Dec;24(5-6):325-32
references: 10091002
references: Neurobiol Dis. 2013 Feb;50:201-8
references: 23103420
references: Invest Ophthalmol Vis Sci. 2004 May;45(5):1531-43
references: 15111612
references: Eur J Neurosci. 2004 May;19(10):2703-10
references: 15147304
references: Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7561-6
references: 10852968
references: Prog Neurobiol. 1987;28(1):55-96
references: 2881324
references: Am J Ophthalmol. 1989 Dec 15;108(6):636-42
references: 2596542
references: Eur J Pharmacol. 2003 Apr 11;466(1-2):31-9
references: 12679139
references: Brain Res. 1997 Aug 8;765(1):135-40
references: 9310404
references: Eur J Neurosci. 1994 Jul 1;6(7):1100-12
references: 7952290
references: Exp Brain Res. 1979 Mar 9;35(1):85-95
references: 436991
references: J Neurosci. 2012 Feb 1;32(5):1847-58
references: 22302823
references: Mol Pharmacol. 2005 Dec;68(6):1656-68
references: 16129735
references: Brain Res. 1977 Jan 14;120(1):151-7
references: 832113
references: Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1198-207
references: 19815732
references: Neurobiol Dis. 2004 Mar;15(2):351-60
references: 15006705
references: Neuroreport. 1994 Oct 3;5(15):1977-80
references: 7841389
references: BMC Neurosci. 2010 Mar 03;11:31
references: 20199668
references: Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3188-96
references: 16123418
references: Biol Psychiatry. 2002 Nov 1;52(9):880-6
references: 12399141
references: Trends Neurosci. 1988 Sep;11(9):405-10
references: 2469207
references: Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4567-75
references: 19443723
references: Vis Neurosci. 2007 Jul-Aug;24(4):523-33
references: 17686198
references: Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2391-7
references: 10476807
references: Jpn J Pharmacol. 1998 Jan;76(1):87-95
references: 9517408
references: Exp Eye Res. 1996 Jul;63(1):105-12
references: 8983955
references: Exp Eye Res. 2006 Nov;83(5):1135-45
references: 16928373
references: Brain Res Bull. 2004 Feb 1;62(5):413-23
references: 15168907
references: Brain Behav Evol. 1977;14(3):185-216
references: 856398
references: Biophys J. 1995 Feb;68(2):501-6
references: 7696503
references: J Neurochem. 1998 Sep;71(3):946-59
references: 9721720
references: J Neurosci. 2007 Oct 17;27(42):11315-26
references: 17942726
references: Nature. 2004 Aug 5;430(7000):631-9
references: 15295589
references: Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1096-106
references: 11274091
references: J Physiol. 2005 Feb 15;563(Pt 1):119-37
references: 15611037